News ICON Public Limited Company

Equities

ICLR

IE0005711209

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 05/06/2026 BST			5-day change	1st Jan Change
149.45 ^USD	-2.19%		+9.83%	-17.98%

06-01	Analyst recommendations: Caesars Entertainment, Dell Technologies, AMD, Dycom Industries…
05-29	Truist Raises Price Target on ICON to $159 From $139, Keeps Hold Rating	MT

All News

Mentions Relevance

05-29	Truist Raises Price Target on ICON to $159 From $139, Keeps Hold Rating	MT
05-29	RBC Raises Price Target on ICON to $126 From $123, Keeps Sector Perform Rating	MT
05-28	ICON Public Limited Company, Q4 2025 Earnings Call, May 28, 2026
05-28	Icon Public Limited Company Provides Earnings Guidance for the Full Year 2026	CI
05-28	Deutsche Bank Adjusts ICON Price Target to $180 From $160, Maintains Buy Rating	MT
05-27	ICON Fiscal Q4 Adjusted Earnings Fall, Revenue Rises	MT
05-27	Icon PLC: Q4 Earnings Snapshot	AQ
05-27	ICON Reports Fourth Quarter and Full Year 2025 Results and Provides Outcome of Audit Committee Investigation	BU
05-27	ICON plc Announces Board Changes	CI
05-27	Tranche Update on ICON Public Limited Company's Equity Buyback Plan announced on February 19, 2025.	CI
05-27	ICON Public Limited Company Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
05-26	ICON Schedules Fourth Quarter and Full Year 2025 Earnings Conference Call and Acknowledges Receipt of Deficiency Notice from Nasdaq	BU
05-18	Icon Set to Benefit From Rising Clinical Trial Activity, Strong Relationships With Large Pharma, RBC Says	MT
05-13	Icon expands US early phase research capabilities with new clinic and outpatient centres	RE
05-13	Icon Opens New Clinical Facilities in Move to Expand Early-Phase Capabilities	MT
05-13	ICON expands US early phase research capabilities with new clinic and outpatient centres	BU
05-13	Icon plc Expands Early Phase Research Capabilities with New Clinic and Outpatient Centres	CI
04-29	ICON Provides Update on Audit Committee Investigation and Timing of Fourth Quarter and Full Year 2025 Financial Results	BU
03-24	Icon, Advarra Collaborate to Develop Site Network Model for Clinical Trials	MT
03-24	ICON and Advarra Introduce New ‘Research-Ready,’ Connected Site Network Model	BU
03-24	Icon and Advarra Introduce New Research-Ready Connected Site Network Model	CI
03-16	Lowey Dannenberg, P.C. is Investigating ICON PLC (NASDAQ: ICLR) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm	AQ
03-10	An undisclosed buyer acquired an unknown minority stake in ICON Public Limited Company from Polen Capital Management, LLC.	CI
02-23	ICON Shares Rise After Jefferies Upgrade	MT
02-23	Jefferies Upgrades ICON to Buy From Hold, Adjusts Price Target to $135 From $175	MT